Drugs / Sym021
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05162755 | Oct 2021 → Feb 2024 | cancer | Servier | Completed | No outcome recorded |
| Phase 1 | NCT04672434 | Nov 2020 → Nov 2024 | metastatic malignant neoplasm | Symphogen A/S | Completed | No outcome recorded |
| Phase 1 | NCT04641871 | Oct 2020 → Jun 2024 | metastatic malignant neoplasm | Symphogen A/S | Completed | No outcome recorded |
| Phase 1 | NCT03311412 | Nov 2017 → Mar 2022 | lymphoma, metastatic malignant neoplasm | Symphogen A/S | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Sym021 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05162755 ↗ |
| Action | Inhibit | “blocks binding of the inhibitory ligands PD-L1 and PD-L2” NCT03311412 ↗ |
| Modality | Monoclonal antibody | “Sym021 is a humanized anti-PD-1 antibody.” NCT04672434 ↗ |
| Route | Intravenous | “by IV infusion” NCT03311412 ↗ |